A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well differentiated metastatic pancreatic neuroendocrine tumors
interventional
N/A
1 country
5
The aim of this study is to investigate whether ramucirumab in combination with dacarbacine has an effect on the disease-control in patients with progressive pancreatic neuroendocrine tumors
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 23, 2024
Actual (reported)Disease control rate (DCR) after 6 months from study entry, determined according to RECIST 1.1 or death
- Objective tumor response (ORR) - progression-free survival (PFS) - overall survival (OS) - toxicity - biochemical response (tumor marker chromogranin A; in cases of functional NET: gastrin, insulin) - Quality of Life (EORTC QLQ-C30 questionnaire) Translational research: - Predictive biomarkers (circulating VEGF, ANGPT1/2 and IL8 levels, immunohistochemical VEGFR2 expression)
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Cyramza 10 mg/ml concentrate for solution for infusion
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Cyramza 10 mg/ml concentrate for solution for infusion
Named ingredient: Ramucirumab
View registry recordMartin-Luther-Universitaet Halle-Wittenberg
Halle (Saale), 06120, Germany
Zentralklinik Bad Berka GmbH
Bad Berka, 99437, Germany
Universitaetsmedizin Goettingen
Goettingen, 37075, Germany
Prof. Dr. med. Patrick Michl
First Submitted
September 23, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.
Universitaetsklinikum Heidelberg AöR
Heidelberg, 69120, Germany
Philipps-Universitaet Marburg
Marburg, 35043, Germany